Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
This article begins with a review of the natural history of chronic myelogenous leukemia (CML), with an emphasis on prognostic features. Current standard therapy of CML with interferon-alpha based regimens, and interferon-alpha, in the context of allogenic stem cell transplantation is then discussed. Finally, some potentially effective novel agents including homoharringtonine, decitabine, ATRA, and topotecan are described.
Kantarjian
H M
HM
Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, USA.
Giles
F J
FJ
O'Brien
S M
SM
Talpaz
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000503:physiopathology; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D014184:Transplantation, Homologous
D016898:Interferon-alpha